drugset / Trial / NCT03294694
Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial is studying the drug Ribociclib (LEE011) in combination with an immunotherapy drug called PDR001 (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone-receptor-positive (HR+), HER2-negative breast cancer (in combination with fulvestrant) or metastatic epithelial ovarian cancer. The names of the medications involved in this study are: * Ribociclib (LEE011) * PDR001 * Fulvestrant
Timeline
- Start
- 2017-11-08
- Primary completion
- 2020-10-14
- Completion
- 2020-10-14
Outcome
Outcome not reported
Stopped: “Safety Implications”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | — |
| Subject | Ribociclib | Small molecule | — | Oral |
| Subject | Spartalizumab | Monoclonal antibody | — | Intravenous |